

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kuberasampath et al.

Serial No: 09/597,517

Filed: June 20, 2000

For: Method for Reducing Tissue Damage
Associated with Ischemia-Reperfusion
or Hypoxia Injury



Attorney Docket No. CIBT-P07-503

Art Unit: 1646

Examiner: E. Kemmerer

TECH CENTER 1600/2900

JUN 13 2002

RECEIVED

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

May 28, 2002

Date of Signature
and of Mail Deposit

A handwritten signature in black ink, appearing to read "Brent LaBarge".

Commissioner for Patents
Washington, D.C. 20231

REPLY UNDER 37 CFR 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed January 28, 2002, in connection with the above application. Please enter the following amendments:

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

B1 Sub 3. (Amended) A method for alleviating tissue destructive effects associated with an inflammatory response to an injured tissue in a mammal, comprising administering to said mammal an agent that stimulates *in vivo* a therapeutically effective concentration of an endogenous morphogen having an amino acid sequence selected from at least one of
(a) an amino acid sequence sharing at least 70% homology with the C-terminal seven-cysteine skeleton of human OP-1, amino acids 38-139 of SEQ ID NO: 5,